Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): A multicentre randomised open-label clinical trial

Annals of the Rheumatic Diseases

Volumn 70, Issue 9, 2011, Pages 1605-1612

  Tynjälä, Pirjo ^a   Vähäsalo, Paula ^b   Tarkiainen, Maarit ^a   Kröger, Liisa ^c   Aalto, Kristiina ^a   Malin, Merja ^d   Putto Laurila, Anne ^e   Honkanen, Visa ^a   Lahdenne, Pekka ^a  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADRENAL INSUFFICIENCY; ANOREXIA; ARTICLE; BONE EROSION; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NIGHTMARE; ONSET AGE; OPEN STUDY; PAIN; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SPORT INJURY; SWELLING; SYNOVITIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VIRUS PNEUMONIA; WEIGHT REDUCTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; EPIDEMIOLOGIC METHODS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; INJECTIONS, INTRA-ARTICULAR; MALE; METHOTREXATE; SULFASALAZINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051470174     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.143347     Document Type: Article

References (32)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
3. Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62. (Pubitemid 41612224)
4. Flatø B, Hoffmann-Vold AM, Reiff A, et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 2006;54:3573-82. (Pubitemid 44737169)
5. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000;39:198-204. (Pubitemid 30139356)
6. Bowyer SL, Roettcher PA, Higgins GC, et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 2003;30:394-400. (Pubitemid 36152610)
7. Bartoli M, Tarò M, Magni-Manzoni S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:370-4. (Pubitemid 351281273)
8. Magnani A, Pistorio A, Magni-Manzoni S, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009;36:628-34.
9. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
10. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201. (Pubitemid 38924397)
11. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66. (Pubitemid 40530232)
12. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808- 16.
13. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73. (Pubitemid 29219206)
14. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
15. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9. (Pubitemid 30151920)
16. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106. (Pubitemid 47502757)
17. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
18. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504. (Pubitemid 351705939)
19. Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009;11:216.
20. Woo P. Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol 2009;21:552-7.
21. Uses and Administration of Corticosteroids. Triamcinolone. In: Martindale: The Complete Drug Reference from the Royal Pharmaceutical Society of Great Britain. Micromedex Database. https://www.thomsonhc.com/home/dispatch/ PFDefaultActionId/pf.LoginAction (accessed 23 March 2011).
22. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
23. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22.
24. Lahdenne P, Vähäsalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7. (Pubitemid 36238089)
25. Magni-Manzoni S, Ruperto N, Pistorio A, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7.
26. Seid M, Opipari L, Huang B, et al. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:393-9.
27. Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8. (Pubitemid 34303799)
28. Raza K, Buckley CE, Salmon M, et al. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2006;20:849-63. (Pubitemid 44382383)
29. Wang SJ, Yang YH, Lin YT, et al. Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol 2002;21:363-8.
30. Burnham JM, Shults J, Dubner SE, et al. Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits. Arthritis Rheum 2008;58:2518-27.
31. Berntson L, Andersson Gäre B, Fasth A, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 2003;30:2275-82. (Pubitemid 37221864)
32. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24.